E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Anti-coagulationtreatment with vitamine K antagonists. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10058768 |
E.1.2 | Term | Vitamin K |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053755 |
E.1.2 | Term | Vitamin K antagonist |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10009728 |
E.1.2 | Term | Coagulation and bleeding analyses |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10043607 |
E.1.2 | Term | Thrombosis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess whether complications of treatment with vitamine K antagonists will decrease when vitamine K is given. To assess to optimal dosage of vitamine K for supplementation. |
|
E.2.2 | Secondary objectives of the trial |
The possible influence of genetic polymorphisms of enzymes CYP2C9 and VKORC1 on the effect of vitamine K supplementation. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Start treatment with vitamin K antagonists less then 4 weeks before inclusion. 2. Treatment with vitamin K antagonists for a minimal period of 6 months, with the therapeutic range of INR between 2.5 and 3.5. 3. Age between 18 and 85 years. 4. Measurement of the INR by the Thrombosis Service Leiden. 5. Informed consent. |
|
E.4 | Principal exclusion criteria |
1. Treatment for liver failure. 2. Dialysys, both peritoneal as hemodialysys. 3. Pregnancy or wish to get pregnant, lactational period. 4. Known to have a chronic condition with a life expectancy of less than 6 months. 5. An expected interruption of treatment with oral anticoagulants for one week or longer. 6. Participation of the self management protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. The number of complications of treatment with vitamin K antagonists per patiëntyear in the group with vitamin K suppletion compared with the placebogroup. 2. The influence of genetic polymorphism of both CYP2C9 and VKORC1 on the effect of vitamin K suppletion while being treated with vitamin K antagonists.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end 6 months after the last patiënt was included and randomised. After the trial ends patiënts will be monitored for four weeks more to assess whether their current dosage of vitamin K antagonists is still the optimal dosage.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |